Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc.

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines

Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

Perceptive Advisors

Jennison Associates

Surveyor Capital

T. Rowe Price

venBio Select Advisor

Cowen Investment Management

Deerfield Capital Management

Fidelity Management and Research Company

Franklin Templeton

Gilead Sciences

Allogene Therapeutics

Today, we honor the remarkable legacy of Dr. Martin Luther King Jr. His tireless dedication to equality, justice, and unity continues to inspire generations. $ALLO #MLK #DEIB

We look forward to presenting at the 42nd annual J.P. Morgan Healthcare Conference. Join us live or tune in to our webcast on Wednesday, January 10 at 8:15 am PT to learn more about our 2024 Vision and plans to redefine the future of CAR T. $ALLO #CART https://lnkd.in/eutcVm_C

We are pleased to announce a strategic partnership with Foresight Diagnostics Inc. The ability to pair our investigational "off-the-shelf" CAR T product with an accurate biomarker has provided the pathway to introduce CAR T in first-line LBCL. https://lnkd.in/guh_r569

Today Allogene announced a bold 2024 Platform Vision that aims to redefine the future of CAR T by leveraging the unique attributes of an allogeneic product. #CART $ALL0 https://lnkd.in/gC-qW-8P

Learn more about Allogene's 2024 Platform Vision and plans to redefine the future of CAR T. Join our upcoming conference call tomorrow at 2pm PT. https://lnkd.in/ga_kkBK5

Always grateful to get our team together for some much-deserved fun at the end of a busy year. Wishing you all safe and happy holiday!

Greater access to CAR T means both efficiacy and safety must be addressed. See our latest research at #ASH2023 booth #3205
https://lnkd.in/gDPBDdRD

The countdown to #ASH23 has begun! Visit our exhibit at booth #3205 and learn how AlloCAR T™ product candidates could fuel the next wave in cell therapy.

As CAR Ts change the treatment landscape, patient demand is straining the system. Could an "off-the-shelf” CAR T product usher in the next treatment wave? #CART #STATSummit2023

The #CART Story is far from being fully written! Our EVP of R&D and CMO, Zachary J Roberts MD PhD shares, "My hope for the future of cancer treatment is that we as a community continue to make breakthroughs that bring us closer to a cure."

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-211.50M -	-184.59M 12.72%	-250.22M 35.55%	-257.00M 2.71%	-332.63M 29.43%	-327.26M 1.61%
depreciation and amortization	1.50M -	5.03M 235.13%	7.59M 50.91%	10.45M 37.81%	14.29M 36.74%	14.20M 0.67%
deferred income tax	-117K -	-331K 182.91%	4.40M 1,430.51%	10.40M 136.13%	8.08M 22.31%	7.50M 7.14%
stock based compensation	18.57M -	46.06M 148.10%	65.26M 41.68%	80.82M 23.84%	83.60M 3.44%	65.95M 21.11%
change in working capital	12.10M -	-6.88M 156.86%	53.92M 883.98%	-32.09M 159.51%	3.71M 111.55%	-15.30M 512.98%
accounts receivables
inventory
accounts payables	8.80M -	-985K 111.19%	615K 162.44%	-767K 224.72%	4.87M 734.68%	-7.50M 254.11%
other working capital	3.30M -	-5.89M 278.79%	53.31M 1,004.58%	-31.32M 158.76%	-1.16M 96.29%	-7.80M 571.51%
other non cash items	134.81M -	3.36M 97.51%	3.96M 17.60%	2.61M 33.98%	2.43M 6.82%	17.18M 606.33%
net cash provided by operating activities	-44.65M -	-137.35M 207.59%	-115.09M 16.20%	-184.81M 60.58%	-220.52M 19.32%	-237.73M 7.81%
investments in property plant and equipment	-3.23M -	-50.79M 1,470.53%	-65.96M 29.86%	-21.45M 67.49%	-5.19M 75.80%	-1.52M 70.80%
acquisitions net		-5.08M -	439.17M 8,753.50%	-17.71M 104.03%	-111.35M 528.74%
purchases of investments	-649.31M -	-252.63M 61.09%	-1.04B 310.72%	-525.58M 49.35%	-248.11M 52.79%	-438.63M 76.79%
sales maturities of investments	21.84M -	472.58M 2,063.72%	598.43M 26.63%	728.39M 21.72%	359.46M 50.65%	603.43M 67.87%
other investing activites	-2.10M -		-439.17M -		111.35M -
net cash used for investing activites	-632.80M -	164.08M 125.93%	-505.12M 407.84%	163.66M 132.40%	106.16M 35.13%	163.29M 53.82%
debt repayment
common stock issued	343.69M -	54.22M 84.22%	621.93M 1,047.08%	11.96M 98.08%	489K 95.91%	91.11M 18,532.31%
common stock repurchased		1.78M -	2.84M 59.45%	3.62M 27.22%	2.46M 31.96%	2.50M 1.42%
dividends paid
other financing activites	427.49M -	2.96M 99.31%	8.81M 198.01%	-3.62M 141.03%		2.09M -
net cash used provided by financing activities	771.18M -	58.96M 92.35%	633.59M 974.61%	11.96M 98.11%	2.95M 75.34%	95.69M 3,143.90%
effect of forex changes on cash
net change in cash	93.73M -	85.69M 8.57%	13.38M 84.39%	-9.19M 168.74%	-111.41M 1,111.77%	21.25M 119.07%
cash at beginning of period		93.73M -	179.43M 91.43%	192.80M 7.45%	183.61M 4.77%	72.20M 60.68%
cash at end of period	93.73M -	179.43M 91.43%	192.80M 7.45%	183.61M 4.77%	72.20M 60.68%	93.45M 29.44%
operating cash flow	-44.65M -	-137.35M 207.59%	-115.09M 16.20%	-184.81M 60.58%	-220.52M 19.32%	-237.73M 7.81%
capital expenditure	-3.23M -	-50.79M 1,470.53%	-65.96M 29.86%	-21.45M 67.49%	-5.19M 75.80%	-1.52M 70.80%
free cash flow	-47.89M -	-188.14M 292.89%	-181.05M 3.77%	-206.26M 13.92%	-225.71M 9.43%	-239.25M 6.00%

COM:ALLOGENE

Allogene Therapeutics, Inc.

Last Close

2.11

22/11 21:00

Market Cap

498.99M

Beta: -

Volume Today

1.42M

Avg: -

Preview